Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL
NCT05583071 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2025-08-13
Summary
Pilot-trial of Methotrexate, Tafasitamab (Minjuvi®), Lenalidomide (Revlimid®) and Rituximab in patients ineligible for HCT-ASCT with Primary Central Nervous System Lymphoma (PCNSL)
Conditions
Interventions
- DRUG
-
Tafasitamab
IV
- DRUG
-
Oral
- DRUG
-
IV
- DRUG
-
Methotrexate
IV
Sponsors & Collaborators
- collaborator INDUSTRY
-
University of Cologne
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-08-23
- Primary Completion
- 2027-02-28
- Completion
- 2027-04-30
Countries
- Germany
Study Locations
More Related Trials
-
R-MTX-zanbrutinib in Secondary CNS Lymphoma
NCT05398224 ·Status: UNKNOWN ·Phase: PHASE2
-
Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine
NCT00503594 ·Status: UNKNOWN ·Phase: PHASE2
-
Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT
NCT05896007 ·Status: RECRUITING ·Phase: PHASE2
-
Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma
NCT02113007 ·Status: TERMINATED ·Phase: PHASE2
-
Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma
NCT00005631 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma
NCT03558750 ·Status: TERMINATED ·Phase: PHASE1
-
Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)
NCT03703167 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)
NCT04129710 ·Status: RECRUITING ·Phase: PHASE2
-
Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma
NCT04934579 ·Status: COMPLETED ·Phase: PHASE2
-
Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma
NCT06730542 ·Status: RECRUITING ·Phase: PHASE1
-
Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab
NCT00609869 ·Status: COMPLETED ·Phase: PHASE2
-
The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study
NCT07240194 ·Status: RECRUITING ·Phase: PHASE2
-
R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II Stuty
NCT04120350 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma
NCT04938297 ·Status: RECRUITING ·Phase: PHASE2
-
Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma
NCT00072449 ·Status: TERMINATED ·Phase: PHASE2
-
Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
NCT04481815 ·Status: RECRUITING ·Phase: PHASE2
-
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
NCT05351593 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL
NCT05390749 ·Status: RECRUITING ·Phase: PHASE2
-
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
NCT06475235 ·Status: RECRUITING ·Phase: PHASE1
-
Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)
NCT03581942 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
NCT07255963 ·Status: RECRUITING ·Phase: PHASE2
-
Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
NCT01145495 ·Status: COMPLETED ·Phase: PHASE2
-
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
NCT04609046 ·Status: RECRUITING ·Phase: PHASE1
-
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
NCT00295932 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Primary Rituximab and Maintenance
NCT00140582 ·Status: COMPLETED ·Phase: PHASE3